WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved a new long-acting respiratory syncytial virus (RSV) vaccine for adults aged 60 and older, expanding the nation's options for preventing severe respiratory disease among high-risk populations.

Health officials say the newly approved vaccine is designed to provide longer-lasting protection against RSV, a virus that can lead to serious complications, including pneumonia and hospitalization, particularly among older adults and people with weakened immune systems.

Medical experts believe the approval comes at an important time as healthcare providers prepare for the annual respiratory virus season. Hospitals and clinics across the United States are expected to incorporate the new vaccine into preventive care programs aimed at reducing severe illness and easing pressure on healthcare systems.

Public health specialists note that vaccination remains one of the most effective ways to reduce the risk of serious respiratory infections. They encourage eligible adults to discuss vaccination options with their healthcare providers, particularly those with chronic heart disease, lung disease, diabetes, or other conditions that increase the risk of complications.

The FDA's latest approval reflects continued investment in vaccine innovation and preventive medicine, reinforcing the United States' leadership in biomedical research and helping improve long-term public health outcomes.